Roy A. Jensen, M.D.

Contact Information:
University of Kansas Medical Center
3901 Rainbow Boulevard
4030 Robinson
Mail Stop 1027
Kansas City KS 66160-7312

Office: 4030 Robinson
Phone: (913) 588-4700
Fax: (913) 588-4701
Email: rjensen@kumc.edu

Laboratory: Wahl Hall East 1002, 1003, 1004, 1005
Phone: (913) 588-0583

Training:

Doctoral Degree: M.D., Vanderbilt University, 1984
Residency Training: Anatomic Pathology, Vanderbilt University Hospital, 1984-1987
Postdoctoral Fellowship: American Cancer Society Clinical Oncology Fellow, 1987-1988
Postdoctoral Fellowship: National Institutes of Health, National Cancer Institute, Biotechnology Training Fellow, 1988-1991

Academic Position(s):

Director, Kansas Masonic Cancer Research Institute
William R. Jewell, MD, Distinguished Kansas Masonic Professor
Professor, Division of Cancer & Developmental Biology, Department of Pathology and Laboratory Medicine, University of Kansas Medical Center
Professor, Department of Anatomy & Cell Biology, University of Kansas Medical Center (joint appointment)

KUMC Center/Institute Affiliation(s):

Director, University of Kansas Cancer Center
Director, Kansas Masonic Cancer Research Institute
Director, Laboratory of Cellular and Molecular Pathology

Research Interests:

The Laboratory of Cellular and Molecular Pathology is interested in the characterization of premalignant and malignant breast lesions, particularly the earliest genetic alterations that result in breast neoplasia, and the transition from in situ disease to invasion. We are currently investigating these changes by proteomic-based discovery analysis via MALDI-TOF mass spectroscopy paired with Laser Capture Microdissection. The overall goal is to elucidate changes in proteomic expression between the epithelial and stromal components of normal, premalignant, and malignant breast tissue and to exploit these differences to develop novel agents that can serve as effective therapeutic or preventive treatments.

In addition, we are in the process of characterizing a series of wild type human and mutant BRCA1 constructs in transgenic mice. These mice appear to have a number of interesting phenotypes in regards to development, differentiation, and susceptibility to carcinogen challenge in comparison to wild-type controls. Future studies will examine the tumor susceptibility of mice crossbred with dominant transgenic oncogenes and the effect of gene dosage on phenotype.

Clinical Interests:

Breast pathology with a special interest in premalignant and malignant breast disease.

Selected recent publications:

• Xu BJ, Sanders ME, Jensen RA, and Caprioli RM: Direct Analysis of Laser Capture Microdissected Cells by MALDI Mass Spectrometry. Journal of the American Society of Mass Spectrometry 13: 1292-1297, 2002.
• Page DL, Schuyler, PA, Dupont WD, Jensen RA, Plummer WD, and Simpson JF: Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study. Lancet 361: 125-129, 2003.
• Jensen RA, and Page DL: Ductal Carcinoma in situ of the Breast: Impact of Pathology on Therapeutic Decisions. American Journal of Surgical Pathology 27(6): 828-831, 2003.
• Campbell M, Qu S, Wells S, Sugandha H, and Jensen RA: An adenoviral vector containing an Arg-Gly-Asp (RGD)-integrin binding motif in the fiber knob enhances protein product levels from transgenes refractory to expression. Cancer Gene Therapy, 10: 559-570, 2003.
• Gorska AE, Jensen RA, Shyr Y, Aakre ME, Bhowmick NA and Moses HL: Transgenic Mice Expressing a Dominant-Negative Mutant Type II TGF-B Receptor Exhibit Impaired Mammary Development and Enhanced Mammary Tumor Formation. American Journal of Pathology 163: 1539-1549, 2003.
• Chaurand P, Sanders ME, Jensen RA, and Caprioli RM: Proteomics in diagnostic pathology: the promise of molecular profiles for cancer diagnosis and prognosis. American Journal of Pathology, 165: 1057-1068, 2004.
• Yee CJ, Hoshino A, Townsend RL, Woltjer RL, Campbell M, Holt JT, Moses HL, and Jensen RA: Effects of BRCA1 Transgene Expression on Murine Mammary Gland Development. American Journal of Pathology, submitted.